@article { 55138,
	title = {Potentiality of a newer oral antihyperglycemic combination therapy over conventional one},
	year = {9999},
	note = {Got Travel Grant $1,000.00 CAD from “Canadian Society for Clinical Pharmacology AND National Research Council of Canada”, for attending the “THE IXth WORLD CONFERENCE ON CLINICAL PHARMACOLOGY AND THERAPEUTICS” going to be held at QUEBEC, CANADA. 2008 July 27- August 01.},
	month = {2008 July 27},
	address = {Quebec, Canada.},
	abstract = {Potentiality of a Newer Oral Antihyperglycemic Combination Therapy over
Conventional One
P. V. Ingle, V. G. Kuchake, A. R. Tekade, P. H. Patil, S. J. Surana,
P. P. Bhattad, Senthamarai. R., Ismail. A. M., G. S. Talele.
1R. C. Patel College of Pharmacy, Shirpur, India, 2Periyar College of Pharmaceutical
Sciences for Girl’s, Tiruchirappalli, India, 3Jalgaon Zillha Medicine Dealers Society’s
College of Pharmacy, Mamurabad, India
The Aim of this study is to perceive the “Potentiality of a newer oral antihyperglycemic
combination therapy over conventional ones” & “aid and assist” the people with type 2
diabetes mellitus. Main objective is to compare efficacy of newer oral antihyperglycemic
combination therapy over conventional ones in the therapy of type 2 diabetes mellitus by
finding out the effect of these two varied combinations on glycemic control by monitoring
fasting plasma glucose (FPG), glycosylated haemoglobin (HbA1c), the Lipid Profile and
the body mass index (BMI). Major Findings - In the glibenclamide plus metformin
combination therapy (n = 23) group FPG & HbA1c decreased during the therapy
significantly up to − 49.06 mg/dL & − 0.90 % respectively during the 4 months of study
period. In the glimepiride plus metformin combination therapy group (n = 15) FPG &
HbA1c decreased during the therapy significantly up to − 55.44 mg/dL & − 1.28 %
respectively during the 4 months of study period. It was found that combination therapy
with metformin plus glimepiride is more effective than glibenclamide plus metformin in
improving glycemic control in type 2 diabetes mellitus and is a beneficial adjunct to
diet/exercise in management of type 2 diabetes mellitus. At the end of the study period in
glimepiride combination therapy more patients were observed to have ≤ 8% of HbA1c
(60.00 %) as compared to glibenclamide combination therapy (39.13 %). Reduction in
BMI and in total and LDL cholesterol level were not too significant.},
	keywords = {Diabetes mellitus, Glycosylated hemoglobin, HbA1c },
	author = {P. V. Ingle and V. G. Kuchake and A. R. Tekade;P. H. Patil and S. J. Surana;P. P. Bhattad;Senthamarai. R and Ismail. A. M and G. S. Talele}
}